Adrian Budhram

Introduction/Aims Line blot (LB) is in widespread use for myositis antibody detection. Yet, studies of its positive predictive value (PPV) in patients with suspected idiopathic inflammatory myopathy (IIM), which would be of particular relevance to neuromuscular clinicians, are lacking. We aimed to determine the PPV of myositis antibody LB testing in patients with suspected IIM, and examine whether PPV was significantly impacted by intensity of antibody positivity. Methods This was a retrospective study of patients who underwent myositis antibody LB testing for suspected IIM between March 2019 and August 2022. Results Of 70 patients who underwent testing for suspected IIM and had positive myositis antibody LB results, 43 (61%) were female and the median age was 61 years (range: 10–83 years). Forty‐four were classified as true‐positives, yielding a PPV of 63%. The PPV of patients with weak‐positive myositis antibody results (14/30, 47%) was significantly lower than the PPV of patients with moderate‐positive or strong‐positive myositis antibody results (30/40, 75%) ( p = .02). Discussion Our study found that myositis antibody LB testing in patients with suspected IIM had a modest PPV, underscoring the need for antibody interpretation in the context of all available clinical and ancillary test data to avoid misdiagnosis. The significantly lower PPV in patients with weak‐positive results emphasizes the particular importance of clinical correlation in such patients. Further study into the diagnostic performance of various LBs for myositis antibody detection is needed to inform their interpretation in clinical practice.